1.37 -0.04 (-2.84%) | 04-26 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 3.3 | 1-year : | 4.39 |
Resists | First : | 2.83 | Second : | 3.75 |
Pivot price | 1.65 | |||
Supports | First : | 1.33 | Second : | 1.1 |
MAs | MA(5) : | 1.4 | MA(20) : | 1.77 |
MA(100) : | 6.39 | MA(250) : | 9.07 | |
MACD | MACD : | -0.4 | Signal : | -0.5 |
%K %D | K(14,3) : | 10.2 | D(3) : | 8.7 |
RSI | RSI(14): 35.1 | |||
52-week | High : | 12.8 | Low : | 1.33 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CERO ] has closed above bottom band by 18.9%. Bollinger Bands are 59.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 1.47 - 1.48 | 1.48 - 1.49 |
Low: | 1.35 - 1.36 | 1.36 - 1.37 |
Close: | 1.35 - 1.37 | 1.37 - 1.39 |
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.
Thu, 28 Mar 2024
KOD, ALLG and SST among mid-day movers - Seeking Alpha
Thu, 28 Mar 2024
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid ... - Markets Insider
Wed, 20 Mar 2024
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket - Markets Insider
Mon, 11 Mar 2024
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Markets Insider
Mon, 11 Mar 2024
US Stocks Down; Dow Falls 100 Points - CERo Therapeutics Hldgs (NASDAQ:CERO), Fangdd Network Group (NASDA - Benzinga
Fri, 08 Mar 2024
Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day ... - Benzinga
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 15 (M) |
Shares Float | 8 (M) |
Held by Insiders | 15 (%) |
Held by Institutions | 5.6 (%) |
Shares Short | 21 (K) |
Shares Short P.Month | 5 (K) |
EPS | 0 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -7.2 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -2 (M) |
Levered Free Cash Flow | 5 (M) |
PE Ratio | 0 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 0 |
Price to Cash Flow | -13.27 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |